FindTrial
Sign In

Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis

Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00059449
Enrollment
372
Registered
2003-04-29
Start date
Unknown
Completion date
Unknown
Last updated
2010-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Necrotizing Enterocolitis, Premature Birth

Keywords

Enterocolitis

Brief summary

Necrotizing enterocolitis (NEC) is a serious gastrointestinal disorder that primarily affects preterm infants. About 10% of babies less than 32 weeks gestation at birth will develop it. Overall, 30% of babies who develop NEC will die from it, with many others developing long term gastrointestinal problems. The most important factor in its development is a premature intestinal tract. Epidermal growth factor (EGF) is an important growth factor in the development and maintenance of the gastrointestinal tract. This study will look for a relationship between EGF levels in premature babies and the development of NEC.

Interventions

None listed

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lead SponsorNIH

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 72 Hours
Healthy volunteers
No

Inclusion criteria

* Gestational Age greater than 23 weeks at birth * Birth weight greater than 500 grams * Age less than 72 hours of life

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026